Last updated: February 14, 2026
Development Status
Cediranib (AZD2171), developed by AstraZeneca, is an oral, small-molecule receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR-1, VEGFR-2, VEGFR-3). It aims to inhibit angiogenesis, which is critical in tumor growth.
As of 2023, phase 2 and 3 clinical trials have been conducted for multiple indications, primarily:
- Ovarian cancer: Phase 2 completed; no recent updates on phase 3 progression.
- Non-small cell lung cancer (NSCLC): Phase 2 data published, but no subsequent phase 3 trials announced.
- Glioblastoma: Several early trials failed to demonstrate significant efficacy.
- Other solid tumors: Trials primarily in early phases.
In 2017, AstraZeneca shifted focus away from Cediranib for certain indications due to mixed efficacy results and tolerability issues. Current development activity is limited, with no major ongoing trials announced for new indications as of 2023.
Efficacy and Safety Profile
Clinical data reveal modest efficacy in ovarian cancer, especially when combined with chemotherapeutic agents. Risks include hypertension, diarrhea, fatigue, and hematological toxicities. The drug's tolerability issues have constrained its systemic use.
Regulatory Status
Cediranib has not received FDA or EMA approval for any indication. The lack of regulatory approval constrains commercial prospects and indicates a need for further efficacy and safety data before potential marketing.
Market Projection
Market size assumptions
-
Ovarian cancer: Approximately 295,000 new cases annually worldwide (2018 data). The moderate success of anti-angiogenic agents like bevacizumab supports potential niche use for cediranib, primarily in treatment-resistant populations.
-
NSCLC: About 2.2 million new cases annually globally. Anti-angiogenic drugs like bevacizumab have justified a multi-billion dollar market, but cediranib's limited efficacy results have restrained its penetration.
-
Other indications: Currently limited due to early-stage trials.
Competitive landscape
Cediranib competes against well-established agents:
| Drug |
Target |
Commercial Success |
Key Limitations |
| Bevacizumab |
VEGF-A |
>$7 billion sales globally (2015 estimate) |
Cost, side effect profile |
| Ramucirumab |
VEGFR-2 |
Approved in gastric, NSCLC, and other cancers |
Similar safety concerns |
| Sorafenib |
Multiple kinases |
Multi-billion dollar product |
Broad kinase profile; side effects |
Most competitors have broader indications with more established efficacy profiles and regulatory approvals.
Market Potential (2023-2033)
Market projections are conservative due to Cediranib’s limited clinical development and regulatory status. Assuming future trials show incremental benefits over existing therapies, a niche market could develop:
- Ovarian cancer: Potential $100-200 million annual sales if approved, mainly in therapy-resistant subsets.
- Other solid tumors: Less than $50 million annually, given experimental status.
However, barriers include competition, safety concerns, and limited clinical data. Without new trial data or regulatory approval pathways, cediranib's commercial prospects remain uncertain.
Strategic Opportunities
- Repurposing for combination therapies in resistant tumor populations.
- Biomarker-driven trials to identify responsive subgroups.
- Licensing or partnering for development in emerging markets or niche indications.
Regulatory and R&D Outlook
Further trials demonstrating significant efficacy and manageable toxicity could restore development interest. Currently, AstraZeneca’s pipeline prioritizes other candidates, implying cediranib may remain dormant or exit the pipeline.
Key Takeaways
- Cediranib is a VEGFR inhibitor with limited recent clinical activity and no regulatory approvals.
- Its efficacy is modest relative to established anti-angiogenic agents, and safety concerns limit its use.
- Market potential exists mainly in ovarian cancer and niche indications, estimated at under $200 million annually if approved.
- Competition from drugs like bevacizumab and ramucirumab, combined with past development challenges, constrains commercial prospects.
- Strategic reevaluation or new clinical data are necessary to revive cediranib’s market prospects.
FAQs
-
What clinical indications is cediranib currently approved for?
None; it remains an investigational drug lacking regulatory approval.
-
How does cediranib compare efficacy-wise to similar drugs like bevacizumab?
It has shown modest efficacy in certain cancers but generally underperforms compared to approved agents, partly due to safety and tolerability issues.
-
What are the primary safety concerns with cediranib?
Hypertension, diarrhea, fatigue, and hematological toxicities are consistent adverse events.
-
Can cediranib be repurposed for other indications?
Potentially, if new trial data shows efficacy, especially in resistant cancer subsets or combination therapies.
-
What are the main barriers to cediranib’s commercial success?
Limited efficacy data, safety profile, absence of regulatory approval, and stiff competition from established therapies.
Sources
- AstraZeneca. (2023). Clinical trial registries and pipeline updates.
- Global Cancer Statistics. (2018). CA: A Cancer Journal for Clinicians.
- Market Data. (2022). Anti-angiogenic therapies overview, Evaluate Pharma.
- Oncology Drug Pipeline Analysis. (2023). Pharmaceutical Intelligence.
- Regulatory Agencies. (2023). FDA and EMA drug approval updates.
[1] AstraZeneca Pipeline Information
[2] International Agency for Research on Cancer (IARC)
[3] Evaluate Pharma, 2022
[4] ClinicalTrials.gov
[5] FDA and EMA official websites
